Get the latest Science News and Discoveries
Alzheimer’s drug development pipeline: Positi - EurekAlert
Released on April 24, the 2024 Alzheimer's Drug Discovery Pipeline revealed that there are currently 164 active trials and 127 unique treatments -- a 10% decrease from the previous year that saw a record-high 187 active trials and 141 unique treatments. On the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, and an increase in studies including biomarkers, researchers say that 2024 is a “learning year” for Alzheimer’s drug development.
None
Or read this on Eureka Alert